# Vanda Pharmaceuticals clinical trials: 82 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 82 trials with Vanda Pharmaceuticals as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vanda Pharmaceuticals: 82 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/vanda-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 82
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 25 newest of 82, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 7, 2026 | NCT07686081 | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis | Vanda Pharmaceuticals | Phase 3 | Recruiting | Ulcerative Colitis (UC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686081) |
| March 3, 2026 | NCT07446439 | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Vanda Pharmaceuticals | Phase 3 | Recruiting | Nausea and Vomiting, Obesity | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446439) |
| January 23, 2026 | NCT07362017 | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis | Vanda Pharmaceuticals | Phase 3 | Recruiting | Moderate-to-severe Chronic Plaque Psoriasis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362017) |
| November 3, 2025 | NCT07223632 | Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | Vanda Pharmaceuticals | Phase 1/2 | Active not recruiting | Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD) | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223632) |
| October 28, 2025 | NCT07221578 | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Vanda Pharmaceuticals | Phase 3 | Active not recruiting | Social Anxiety Disorder (SAD) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221578) |
| September 17, 2025 | NCT07179055 | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Vanda Pharmaceuticals | Phase 2 | Recruiting | Dry Eye | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179055) |
| July 29, 2025 | NCT07090161 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | Vanda Pharmaceuticals | Phase 2 | Recruiting | Hypertension, Uncontrolled Hypertension | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090161) |
| July 15, 2025 | NCT07065773 | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis | Vanda Pharmaceuticals | Phase 2 | Active not recruiting | Onychomycosis of Toenail | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07065773) |
| May 8, 2025 | NCT06961968 | Randomized Withdrawal Study in Patients With Schizophrenia | Vanda Pharmaceuticals | Phase 3 | Recruiting | Schizophrenia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961968) |
| May 1, 2025 | NCT06953869 | Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | Vanda Pharmaceuticals | Phase 3 | Recruiting | Insomnia Disorder | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06953869) |
| February 20, 2025 | NCT06836557 | Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | Vanda Pharmaceuticals | Phase 3 | Completed | Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06836557) |
| February 17, 2025 | NCT06830044 | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Vanda Pharmaceuticals | Phase 3 | Recruiting | Major Depressive Disorder (MDD) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06830044) |
| February 3, 2025 | NCT06804603 | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use | Vanda Pharmaceuticals | Phase 2 | Completed | Obesity | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06804603) |
| January 31, 2025 | NCT06803290 | Food Effect Study of VHX-896 in Healthy Volunteers | Vanda Pharmaceuticals | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06803290) |
| November 22, 2024 | NCT06701396 | Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant | Vanda Pharmaceuticals | Phase 3 | Recruiting | Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders, Gene Mutations and Other Alterations... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06701396) |
| July 10, 2024 | NCT06494397 | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions | Vanda Pharmaceuticals | Phase 1 | Completed | Schizophrenia, Bipolar I Disorder | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06494397) |
| March 21, 2024 | NCT06323655 | Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects | Vanda Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06323655) |
| March 6, 2024 | NCT06296966 | A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Vanda Pharmaceuticals | Phase 2 | Unknown | Dry Eye | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06296966) |
| November 18, 2023 | NCT06138613 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | Vanda Pharmaceuticals | Phase 3 | Active not recruiting | Motion Sickness | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06138613) |
| June 15, 2023 | NCT05903924 | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness | Vanda Pharmaceuticals | Phase 3 | Completed | Motion Sickness | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05903924) |
| December 13, 2022 | NCT05648591 | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents | Vanda Pharmaceuticals | Phase 4 | Recruiting | Schizophrenia, Bipolar I Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05648591) |
| October 7, 2022 | NCT05572281 | Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers | Vanda Pharmaceuticals | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05572281) |
| May 9, 2022 | NCT05366855 | Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | Vanda Pharmaceuticals | Phase 3 | Terminated | Generalized Pustular Psoriasis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05366855) |
| May 5, 2022 | NCT05361707 | Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances | Vanda Pharmaceuticals | Phase 3 | Unknown | Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05361707) |
| April 29, 2022 | NCT05352893 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | Vanda Pharmaceuticals | Phase 3 | Completed | Generalized Pustular Psoriasis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05352893) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 19 |
| Phase 1/2 | 2 |
| Phase 2 | 21 |
| Phase 2/3 | 2 |
| Phase 3 | 30 |
| Phase 4 | 2 |
| Not applicable | 1 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 54 |
| Recruiting | 13 |
| Unknown | 4 |
| Terminated | 4 |
| Active not recruiting | 4 |
| Enrolling by invitation | 1 |
| Available | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Sleep Disorders, Circadian Rhythm | 9 |
| Schizophrenia | 8 |
| Sleep Wake Disorders | 7 |
| Chronobiology Disorders | 6 |
| Nervous System Diseases | 5 |
| Blindness | 5 |
| Psoriasis | 5 |
| Nausea | 5 |
| Vomiting | 5 |
| Eye Diseases | 4 |
| Dyssomnias | 4 |
| Dermatitis, Atopic | 4 |
| Motion Sickness | 4 |
| Gastroparesis | 4 |
| Smith-Magenis Syndrome | 3 |
| Sleep Initiation and Maintenance Disorders | 3 |
| Eczema | 3 |
| Autism Spectrum Disorder | 2 |
| Coronavirus Infections | 2 |
| Depressive Disorder, Major | 2 |
| Phobia, Social | 2 |
| Pruritus | 2 |
| Obesity | 2 |
| Dry Eye Syndromes | 2 |
| Liver Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [B2B audio visual production companies in the United States](https://specstream.ai/data/businesses/b2b-audio-visual-production-companies/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
- [Cosmetic surgery practices in the United States](https://specstream.ai/data/businesses/cosmetic-surgery-practices/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
